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Iragorri et al, in this edition of The Journal, report a systematic review of the effect of 
Biologics and Targeted Synthetic drugs on work outcomes in Psoriatic Arthritis. The 
paper raises several points of interest on the challenges facing investigators in the 
assessment of work disability and the current methods of judging the cost effectiveness 
of treatments for Psoriatic Arthritis. 
 
Patient reported work disability has gained increasing traction as an important outcome 
in rheumatic disease in recent years. Work is important to individuals (both financially 
and emotionally) and the economy as a whole. Access to appropriate healthcare is just 
one of the factors that can determine the health of a society (see Figure 1). The ability 
to work can affect an individual’s living conditions, social interactions and have spill 
over effects on future generations (including educational attainment), and therefore 
ensuring that patients can remain in work when suffering chronic disease, or return to 
work as soon as possible after periods of ill health should be a high priority for those 
concerned with the health of the nation. 
 
 
Figure 1: The Dahlgren-Whitehead model 
 
Dahlgren and Whitehead (1991). Used with permission of the Institute for Futures 
Studies, Stockholm, Sweden. 
 
In the context of long term health conditions such as Psoriatic Arthritis (PsA), work 
disability may be significant and treatments to improve functional capability can have 
an impact not only on health related outcomes but also on a patient’s ability to undertake 
productive work. The importance of work for an individual’s health and happiness is 
not a new concept. Galen of Pergamon (AD 172) is attributed with the quote 
‘employment is nature’s physician, and is essential for human happiness’ reflecting the 
central role work plays in the health and well-being of most people. Studies of treatment 
outcomes important to patients consistently rank the ability to work highly, 
demonstrating that the sentiment is as relevant today as it was in Galen’s time.[1, 2] As 
treating clinicians we have never been better placed to control disease and prevent 
disability with the advent of many more effective treatments.  On a societal level the 
advent and rapid uptake of highly effective, but expensive, biologic and targeted 
synthetic Disease Modifying Anti-Rheumatic Drugs (b/tsDMARDS) illustrates the 
need to provide an economic case for the provision of treatments.[3] Such assessments 
are made through cost-effectiveness analysis and there have been calls to also include 
work disability in an assessment of cost-effectiveness.[4] [5] 
 
Iragorri et al, identified placebo Randomised Controlled Trials (RCT’s) of adults with 
PsA that reported a measure of work disability. In total only five trials were judged to 
be at low risk of bias and were included for analysis (treatments were: Infliximab, 
Golimumab, Certolizumab pegol, Ustekinumab and Apremilast). All the treatments 
assessed improved patient reported work disability, but the heterogeneity of outcomes 
used prevented a pooled analysis. The data available for reporting was limited and, of 
the five studies included, only two reported the percentage of patients who were 
employed and two studies did not report on the statistical significance of work 
productivity.[6, 7] The authors conclude that treatment with Infliximab, Golimumab, 
Certolizumab pegol, Ustekinumab and Apremilast improves self-reported work 
disability and can help inform decisions about which treatments should be reimbursed 
by quantifying how each treatment reduced productivity costs.  
 
The review highlights the need to improve consistency in outcome measures collected 
in PsA RCT’s, including secondary endpoints such as work disability, to aid 
quantitative comparisons such as meta analyses. The updated core set of outcome 
measures to be assessed in PsA RCT’s now includes work as an outcome (under the 
umbrella term of Participation).[8] A variety of measures are used to assess worker 
productivity in RCTs and five have been endorsed by Outcome Measures in 
Rheumatology (OMERACT); The Workplace Activity Limitations Scale (WALS), the 
Work Limitations Questionnaire with modified physical demands scale (WLQ 
PDmod), the Work Ability Index (WAI), the Arthritis-specific Work Productivity 
Survey (WPS), and the Work Productivity and Activity Impairment Questionnaire 
(WPAI).[9] Work is currently underway to evaluate the validity of all outcome 
measures used for the assessment of psoriatic arthritis against the OMERACT filter, to 
derive a ‘core set’ of measurement instruments for use in trials. Over time agreement 
on instruments will result in more consistency across trials and greater facility for 
comparison between drugs.  
 
In the review by Iragorri et al only five studies were identified for inclusion from fully 
published articles. Quality of life measures are often secondary end points and are often 
only reported in conference abstract form, as a result relevant studies reporting work 
data may have been missed introducing reporting bias. By example the Work 
Productivity Activity Index (WPAI) was collected as a measure of work productivity 
in the Secukinumab trails in PsA and demonstrated improvement in productivity loss. 
[10, 11] The WPAI is one of the few work outcomes with a PsA specific estimate of 
the Minimal Important Difference (MID)[12].  Observational cohort and registry 
studies were also excluded in the review by Iragorri et al. Non-randomised studies can 
provide important data over longer time frames, in a more ‘real world’ setting 
complimenting RCT data. Data from the British Society of Rheumatology Biologics 
Registry (BSRBR)[13], Danish Biologics Registry DANBIO[14] and a two year, UK 
multicentre study of work disability in PsA[15]  each support the view that work 
disability is prevalent amongst patients with PsA and is improved with better disease 
control, particularly with bDMARDS.   
 
There seems little debate that we should supplement our understanding of the cost 
effectiveness of drugs with data on work disability. To not do so underestimates the 
societal benefit of long term effective disease control and prevention of damage and 
irreversible disability. So the question for clinicians, health economists and health care 
commissioners is how we reflect work employment in an assessment of the cost 
effectiveness of competing alternatives and how we can use the data reported by 
Iragorri et al in this edition of The Journal to inform such assessments? Does the data 
support reimbursement decisions, where healthcare resources are scare, in the absence 
of any quantitative comparisons of work disability between alternative treatments? The 
data presented does not compare one bDMARD or tsDMARD to another therefore it is 
not suitable for making judgements on which agent should be reimbursed, when 
considering any differences in work productivity, however the paper raises a number 
of issues which are relevant to the broader discussion on how we can potentially 
incorporate work productivity (and disability prevention) into the assessment of high 
cost drugs in chronic diseases like PsA.  
 
Iragorri and colleges raise an important point regarding the challenge of including work 
in assessments of cost-effectiveness without indirectly penalising those who do not 
work (or are not in paid employment). So how can we move forward without indirectly 
exacerbating inequalities? Perhaps clinicians, as patient advocates and those who most 
clearly see the how effective amelioration of chronic inflammatory disease enables 
patients to work, should promote employment to be considered in health care. How 
incorporating work in cost-effectiveness assessments can be achieved without 
penalising those in non-paid work (such as childcare) and those who are not in work 
remains to be determined, perhaps by taking an population level view of disease cost  
and work disability factoring work disability inform country specific cost effectiveness 
valuations?  
 
Iragorri et al also emphasise the important issue of perspective for economic analyses. 
For some national health care decision makers the perspective is restricted to costs 
pertaining to the health care service and outcomes are strictly health outcomes. Work 
disability has implications for an individual’s health related quality of life but also 
contributes towards a broader sense of well-being. Many of the costs of work disability 
also fall outside of the health care sector. Inclusion of these wider societal effects of 
treatment raises poses challenges, not only in terms of how to include these, but also 
how the implications for reimbursement on budgets are consolidated across sectors.  
 
The systematic review by Iragorri et al in this edition of The Journal may not tell is 
which drug is most effective at reducing work disability in PsA but, taking a broader 
view, should accelerate the dialogue on cost effectiveness valuations in chronic disease 
in countries with nationalised heal care systems. Local payers may not see the pay-off 
of long term high cost drugs preventing work disability, but prevention of disability 
may resonate with payers in health and social care at government level, particularly 
those taking a broader perspective.  
 
  
References 
1. Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-
derived and patient-reported outcome measure for assessing psoriatic arthritis: 
elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease 
(PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 
2014;73(6):1012-9. Epub 2014/05/03. 
2. Dures E, Hewlett S, Lord J, Bowen C, McHugh N, Group PS, et al. Important 
Treatment Outcomes for Patients with Psoriatic Arthritis: A Multisite Qualitative 
Study. The patient. 2017;10(4):455-62. Epub 2017/02/24. 
3. Nurmohamed MT, Dijkmans BA. Efficacy, tolerability and cost effectiveness 
of disease-modifying antirheumatic drugs and biologic agents in rheumatoid arthritis. 
Drugs. 2005;65(5):661-94. Epub 2005/03/08. 
4. Shepard DS. Cost-effectiveness in Health and Medicine. By M.R. Gold, J.E 
Siegel, L.B. Russell, and M.C. Weinstein (eds). New York: Oxford University Press, 
1996. The Journal of Mental Health Policy and Economics. 1999;2(2):91-2. 
5. Bojke L, Spackman E, Hinde S, Helliwell P. Capturing all of the costs in 
NICE appraisals: the impact of inflammatory rheumatic diseases on productivity. 
Rheumatology. 2012;51(2):210-5. Epub 2012/01/24. 
6. Kavanaugh A, Antoni C, Mease P, Gladman D, Yan S, Bala M, et al. Effect of 
infliximab therapy on employment, time lost from work, and productivity in patients 
with psoriatic arthritis. J Rheumatol. 2006;33(11):2254-9. Epub 2006/09/09. 
7. Kavanaugh A, Gladman D, van der Heijde D, Purcaru O, Mease P. 
Improvements in productivity at paid work and within the household, and increased 
participation in daily activities after 24 weeks of certolizumab pegol treatment of 
patients with psoriatic arthritis: results of a phase 3 double-blind randomised placebo-
controlled study. Ann Rheum Dis. 2015;74(1):44-51. Epub 2014/06/20. 
8. Orbai AM, de Wit M, Mease P, Shea JA, Gossec L, Leung YY, et al. 
International patient and physician consensus on a psoriatic arthritis core outcome set 
for clinical trials. Ann Rheum Dis. 2017;76(4):673-80. Epub 2016/09/11. 
9. Beaton DE, Dyer S, Boonen A, Verstappen SM, Escorpizo R, Lacaille DV, et 
al. OMERACT Filter Evidence Supporting the Measurement of At-work Productivity 
Loss as an Outcome Measure in Rheumatology Research. J Rheumatol. 
2016;43(1):214-22. Epub 2015/09/04. 
10. Strand V, FitzGerald O, Coates L, Walsh J, Cañete J, Bhosekar V, et al. 
FRI0521 Secukinumab provides sustained improvements in work productivity and 
health related quality of life in patients with active psoriatic arthritis: 2-year results 
from future 1 and future 2. Annals of the Rheumatic Diseases. 2017;76(Suppl 2):688-. 
11. Rahman P, Strand V, McInnes IB, Marzo-Ortega H, Dokoupilová E, Churchill 
M, et al. THU0433 Secukinumab Improves Physical Function, Quality of Life, 
Fatigue and Work Productivity in Patients with Active Psoriatic Arthritis in Future 2, 
A Phase 3 Trial. Annals of the Rheumatic Diseases. 2015;74(Suppl 2):356-. 
12. Tillett W, Shaddick G, Boyce B, McHugh NJ, editors. Validity of the Wpai-
SHP in Psoriatic Arthritis and Estimation of the Minimally Important Difference. 
Arthritis & rheumatology; 2017: Hoboken 07030-5774. 
13. Verstappen SM, Watson KD, Lunt M, McGrother K, Symmons DP, Hyrich 
KL. Working status in patients with rheumatoid arthritis, ankylosing spondylitis and 
psoriatic arthritis: results from the British Society for Rheumatology Biologics 
Register. Rheumatology 2010;49(8):1570-7. Epub 2010/05/07. 
14. Kristensen LE, Jorgensen TS, Christensen R, Gudbergsen H, Dreyer L, 
Ballegaard C, et al. Societal costs and patients' experience of health inequities before 
and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis. 
2017;76(9):1495-501. Epub 2017/02/01. 
15. Tillett W, Shaddick G, Jobling A, Askari A, Cooper A, Creamer P, et al. 
Effect of anti-TNF and conventional synthetic disease-modifying anti-rheumatic drug 
treatment on work disability and clinical outcome in a multicentre observational 
cohort study of psoriatic arthritis. Rheumatology (Oxford). 2017;56(4):603-12. Epub 
2016/12/26. 
 
 
